BCR and leukemia: 15 mg·kg−1 (3 doses IV over 24 h) results in a 100% uptake in peripheral blood cells that remain positive until day 10; no liver toxicity or other biochemical alternation; after 10 IV doses over 35 days, luciferase signal decreased 0.75-fold, while it increased in control mice 1.6-fold; 60% knockdown efficiency of BCR-ABL by LNP-anti-BCR-ABL siRNA in sorted leukemia cells from the myelosarcoma mouse tissue